Weekly update Companies AI-cruiter Recruiting

Dermavant Sciences

Founded: 2017

Location: Long Beach, CA

Employee range: 1 - 10

Clinical stage: COM

Therapy area: Psoriasis

Drug types: DRM, IMM

Lead product: VTAMA (DMVT-505)

Product link: https://www.dermavant.com/pipeline/

Funding: $200M Jun 2021; $100M Aug 2018

dermavant.com

linkedin.com

job board

Short description:

Small Molecules for Dermatology Indications

Drug notes:

Also Clin3 atopic dermatitis; DMVT-506 Clin0 Immunological & inflammatory diseases

Long description:

Dermavant is developing and commercializing therapeutics for medical dermatology. The skin is the largest organ of the body and millions of people globally suffer with chronic skin conditions. Dermavant is building a dermatology pipeline of product candidates that target specific unmet needs in two of the largest growing immuno-dermatology conditions - plaque psoriasis and atopic dermatitis. VTAMA®, Dermavant’s lead candidate is a topical formulation that is an agonist for the aryl hydrocarbon receptor. Recently, Dermavant announced positive results from their Phase 3 trial of VTAMA® for patients with Atopic Dermatitis.